Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patient with hematological malignant diseases

References

• Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697–705
   PubMed Web of Science ®Google Scholar
• Pittenger M F, Mackay A M, Beck S C, Jaiswal R K, Douglas R, Mosca J D, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–147
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jahagirdar B N, Reinhardt R L, Schwartz R E, Keene C D, Ortiz-Gonzalez X R, et al. Pluripotency of mesenchymal stem cell derived from adult marrow. Nature 2002; 418: 41–49
   PubMed Web of Science ®Google Scholar
• Koc O, Lazarus H. Mesenchymal stem cells heading to the clinic. Bone Marrow Transplant 2001; 27: 235–239
   PubMed Web of Science ®Google Scholar
• Horwitz E M, Prockop D J, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309–313
   PubMed Web of Science ®Google Scholar
• Weissman I L. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 2000; 287: 1442–1446
   PubMed Web of Science ®Google Scholar
• Devine S M, Hoffman R. Role of mesenchymal stem cells in hematopoietic stem cell transplantation. Curr Opin Hematol 2000; 7: 385–363
   Web of Science ®Google Scholar
• Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722–3729
   PubMed Web of Science ®Google Scholar
• Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42–48
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger M F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815–1822
   PubMed Web of Science ®Google Scholar
• Jiang X X, Zhang Y, Liu B, Zhang S H, Wu Y, Yu X D, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120–4126
   PubMed Web of Science ®Google Scholar
• Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. J Hemtoth Stem Cell 2004; 13: 263–271
   Google Scholar
• Ringdén O, Uzunel M, Rasmusson I, Remberger M, Sundberg B, Lönnies H, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390–1397
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–1441
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579–1586
   PubMed Web of Science ®Google Scholar
• Lazarus H, Curtin P, Devine S, Curtin P, Maziarz R T, Holland H K, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389–398
   PubMed Web of Science ®Google Scholar
• Zhao Z G, Liang Y, Li K, Li W M, Li Q B, Chen Z C, Zou P. Phenotypic and functional comparison of mesenchymal stem cells derived from the bone marrow of normal adults and patients with hematologic malignant diseases. Stem Cells Dev 2007; 16:637–648
   Web of Science ®Google Scholar
• Sayegh M H, Carpenter C B. Transplantation 50 years later – progress, challenges, and promises. N Engl J Med 2004; 351: 2761–2766
   PubMed Web of Science ®Google Scholar
• Noort W A, Kruisselbrink A B, in't Anker P S, Kruger M, van Bezooijen R L, de Paus R A, et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34 (+) cells in NOD/SCID mice. Exp Hematol 2002; 30: 870–878
   PubMed Web of Science ®Google Scholar
• Koc O N, Gerson S L, Cooper B W, Dyhouse S M, Haynesworth S E, Caplan A I, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307–316
   PubMed Web of Science ®Google Scholar
• Tse W T, Pendleton J D, Beyer W M, Egalka M C, Guinan E C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells:Implications in transplantation. Transplantation 2003; 75: 389–397
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Pittenger M F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815–1822
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni P D, Matteucci P, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838–3843
   PubMed Web of Science ®Google Scholar
• Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4619–4621
   PubMed Web of Science ®Google Scholar
• Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228–234
   PubMed Web of Science ®Google Scholar
• Han Q, Sun Z, Liu L, Chen B, Cao Y, Li K, Zhao R C. Impairment in immuno-modulatory function of Flk1(+) CD31(−)CD34(−) MSCs from MDS-RA patients. Leuk Res 2007; 31: 1469–1478
   PubMed Web of Science ®Google Scholar
• Narendran A, Hawkins L M, Ganjavi H, Vanek W, Gee M F, Barlow J W, et al. Characterization of bone marrow stromal abnormalities in a patient with constitutional trisomy 8 mosaicism and myelodysplastic syndrome. Pediatr Hematol Oncol 2004; 21: 209–221
   PubMed Web of Science ®Google Scholar
• Tauro S, Hepburn M D, Bowen D T, Pippard M J. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 2001; 86: 1038–1045
   PubMed Web of Science ®Google Scholar
• Wetzler M, Kurzrock R, Estrov Z, Estey E, Talpaz M. Cytokine expression in adherent layers from patients with myelodysplastic syndrome and acute myelogenous leukemia. Leuk Res 1995; 19: 23–34
   PubMed Web of Science ®Google Scholar
• Wetzler M, Estrov Z, Talpaz M, Kim K J, Alphonso M, Srinivasan R, et al. Leukemia inhibitory factor in long-term adherent layer cultures: increased levels of bioactive protein in leuk and modulation by IL-4, IL-1β, and TNF-α. Cancer Res 1994; 54: 1837–1842
   PubMed Web of Science ®Google Scholar